Welcome to our dedicated page for Lifevantage SEC filings (Ticker: LFVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LifeVantage Corporation (Nasdaq: LFVN) is a Delaware-incorporated health and wellness company that focuses on nutrigenomics and cellular activation, and its SEC filings provide detailed insight into its operations, governance, and financial performance. As a public company, LifeVantage files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy statements on Schedule 14A, among other documents.
Through these filings, investors can review information about LifeVantage’s activator-based product portfolio, which includes the Protandim family, TrueScience Liquid Collagen, the MindBody GLP-1 System, P84, AXIO nootropic energy drink mixes, activation-supporting nutrients, the TrueScience skin and hair care line, and Petandim. The filings also describe the company’s direct selling model, under which independent Consultants sell products to Customers and share the business opportunity with entrepreneurs.
Current reports on Form 8-K document material events such as financial results announcements, executive officer changes, and other significant corporate developments. Definitive proxy statements (DEF 14A) provide detail on board composition, executive compensation, equity incentive plans like the 2017 Long-Term Incentive Plan, and matters submitted to stockholder votes, including director elections, say-on-pay proposals, and auditor ratification. Voting results for these proposals are also reported in 8-K filings.
On this page, LifeVantage filings are updated as they are made available through the EDGAR system. AI-powered tools summarize key sections of lengthy documents, helping readers understand topics such as revenue trends, non-GAAP measures like adjusted EBITDA and adjusted earnings per share, stock-based compensation plans, and governance structures without reading every line. Users can also review disclosures related to dividends, share repurchases, and risk factors referenced in the company’s periodic reports.
For those researching LFVN, this filings archive offers a structured view of LifeVantage’s regulatory history, financial reporting, and corporate decision-making, with AI-generated highlights to make complex filings more accessible.
Lifevantage Corp director Lewis Darwin reported an open-market purchase of common stock. On this transaction date, he bought 1,055 shares at $5.23 per share, increasing his direct holdings to 136,563 shares. This filing shows a modest increase in his personal investment in the company.
LifeVantage Corporation is registering up to $75.0 million of securities on a shelf registration.
The shelf permits the company to offer common stock, preferred stock, debt securities, warrants and units from time to time, in one or more series, with specific terms to be provided in prospectus supplements. The prospectus caps aggregate sales under the shelf at $75.0 million and states offerings may be made through underwriters, dealers, agents or directly.
The company’s common stock trades on the Nasdaq Capital Market under the symbol LFVN; the prospectus cites a last reported sale price of $4.91 per share on March 4, 2026. Shares issued and outstanding were 12,804,772 as of March 4, 2026, and the prospectus reports an aggregate market value of common stock held by non‑affiliates of $65,580,155 based on 12,793,359 outstanding shares as of February 26, 2026.
Lifevantage Corp director Dayton Judd reported open-market purchases of the company’s common stock. He bought 10,500 shares on March 2, 2026 at $4.53, 18,097 shares on February 27, 2026 at $4.63, and 4,600 shares on February 26, 2026 at $4.58, totaling 33,197 shares.
After these transactions, Judd directly owns 80,359 shares. The filing also shows 749,325 shares held indirectly through Sudbury Capital Fund, LP, an investment entity with which he is associated.
LifeVantage director Darwin Lewis bought 3,955 shares of company common stock in an open‑market transaction at a weighted average price of $5.2216 per share. After this purchase on February 9, 2026, he directly owns 135,508 LifeVantage shares.
LifeVantage Corporation filed a current report describing two key updates. The company issued a press release announcing financial results for the three and six months ended December 31, 2025, which is furnished as Exhibit 99.1. The report also discloses that President and Chief Executive Officer Steven R. Fife has decided to retire and will resign as CEO and from the board, with his resignation expected to be effective in April 2026. The company states that Mr. Fife’s decision to retire is not due to any disagreement regarding operations, financial policies, or practices, and additional details are provided in a second press release furnished as Exhibit 99.2.
LifeVantage Corporation reported weaker results for the quarter ended December 31, 2025 as revenue fell to $48.9 million from $67.8 million a year earlier, mainly from lower sales of its MindBody GLP-1 System™. Net income declined to $0.3 million from $2.6 million, with gross margin pressured by about $2.4 million of inventory obsolescence tied to this product line.
For the first six months, revenue was $96.5 million versus $115.0 million, and net income was $2.4 million versus $4.4 million. Active accounts fell 21.2% year over year to 115,000, reflecting fewer independent consultants and customers. The company completed a $4.2 million acquisition of LoveBiome assets, adding a new gut-health product line, and ended the period with $10.2 million in cash and no borrowings on its $5.0 million credit facility.
Lifevantage Corp director Michael Beindorff reported gifting company stock to a family trust. On 11/25/2025, he transferred 7,819 shares of Lifevantage common stock in a transaction coded "G," which indicates a gift with a reported price of $0 per share.
After this transaction, he directly owned 27,570 shares and indirectly held 51,625 shares through the Michael A. Beindorff Trust, where he and his spouse are trustees. Additional indirect holdings include 126 shares held by his spouse as custodian for minor children and 5,500 shares held by his spouse.
LifeVantage Corporation disclosed that two senior executives plan to leave the company in December 2025. On December 3, 2025, Chief Marketing Officer Julie Boyster notified the company of her intention to resign from that role effective December 12, 2025 to pursue other business opportunities.
On the same date, Chief Information and Innovation Officer Todd Thompson informed LifeVantage that he intends to resign from his role effective December 24, 2025, also to pursue other business opportunities. These changes affect the leaders overseeing the company’s marketing and information/innovation functions.
LifeVantage Corp (LFVN) director Michael A. Beindorff reported a sale of company stock in a Form 4 filing. On 11/19/2025, a trust for which he and his spouse serve as trustees sold 12,607 shares of LifeVantage common stock at a weighted average price of $6.4198 per share, with individual trades executed between $6.39 and $6.48. After this transaction, he reported beneficial ownership of 43,806 shares held by the trust, 35,389 shares held directly, 126 shares held by his spouse as custodian for minor children, and 5,500 shares held by his spouse.